App-Quantinova.ai

In vitro and in vivo Actions of Ang1-7/BNP: A Novel Chimeric Peptide With Dual Actions Through the Natriuretic Peptide and Mas Receptors

Brenda K Huntley - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

N/A

Angiotensin II

Incremental Prognostic Significance of the Elevated Levels of Pentraxin 3 in Patients With Heart Failure With Normal Left Ventricular Ejection Fraction

Seigo Sugiyama - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

ILS-969

Severity of Sleep-Disordered Breathing Has an Impact on the Prevalence of Nocturnal Enuresis in Patients With Cardiovascular Disease

Takashi Miyazaki - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sleep apnoea

N/A

Best Use of Cardiac Biomarkers for Left Ventricular Structure in Japanese Patients with Chronic Kidney Disease and a High Risk for Cardiovascular Disease: The Japan Morning Surge - Home Blood Pressure (J-HOP) LVH Study

Michiaki Nagai - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

B-type Natriuretic Peptide Behavior After Pediatric Heart Transplantation: Impact of Ischemic Time

Umar Boston - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Emotional Distress and Perceived Sexual Difficulties in Patients With Stage C Heart Failure and Patients With Left Ventricular Assist Device

Etsuko Nakayama - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Prognostic Value of Combination of Ultra-Sensitive Troponin I and B-Type Natriuretic Peptide in Outpatients with Chronic Kidney Disease

Junnichi Ishii - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Chronic kidney disease

N/A

Impact of Endothelial Dysfunction on Residual Platelet Aggregability after Dual Antiplatelet Therapy with Aspirin and Clopidogrel in Stable Patients with Coronary Artery Disease

Seigo Sugiyama - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Clopidogrel bisulfate

Prognostic Significance of Peripheral Endothelial Dysfunction in Heart Failure With Reduced Left Ventricular Ejection Fraction

Seigo Sugiyama - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Vasodilation dysfunction

N/A

Impact of Aortic Stiffness on Exercise Intolerance in Patients With Reduced Left Ventricular Ejection Fraction

Kazuaki Wakami - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Left ventricular diastolic dysfunction

N/A

Interaction of B-Type Natriuretic Peptide and Cardiac Troponin T Improves the Prediction of Mortality in Patients on Hemodialysis

Ryuunosuke Okuyama - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

Significant Association between Decreased Plasma Levels of Brain-derived Neurotrophic Factor in Heart Failure

Seigo Sugiyama - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Congestive heart failure

N/A

Is a Novel Aortic Stiffness Parameter Cardio-ankle Vascular Index Useful Predictor for Exercise Tolerance?

Nobuyuki Ohte - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Diastolic dysfunction

N/A

Changes in B-type Natriuretic Peptide and Reverse Left Ventricular Remodeling After Restrictive Annuloplasty in Patients with Advanced Cardiomyopathy

Kazuhiro Taniguchi - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Mitral valve regurgitation

N/A

B-type Natriuretic Peptide Promoter-mediated Suppression of Protein Phosphatase 1? Mitigates Pressure Overload-induced Heart Failure in Mice

Yasuhiro Ikeda - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Systolic dysfunction

N/A

Factors Influencing the Development of De Novo Heart Failure in Stage-B Asymptomatic Patients -A Report From the CHART-2 Study-

Yasuhiko Sakata - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Coronary Artery Disease

N/A

Prognostic Value of Serum Sodium Concentrations for Cardiovascular Events in Patients with Heart Failure with Normal Left Ventricular Ejection Fraction

Eiichiro Yamamoto - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

N/A

Novel Predictors of Left Ventricular Reverse Remodeling in Individuals with Recent Onset Dilated Cardiomyopathy

Marek Sramko - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Dilated cardiomyopathy

N/A

Poor Adherence to Medication is an Independent Risk Factor for Adverse Clinical Outcomes in Heart Failure with Reduced Ejection Fraction (HFrEF) but not Heart Failure with Preserved Ejection Fraction (HFpEF)

Koichiro Kinugawa - American Heart Association (AHA) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with preserved ejection fraction

Angiotensin II

Impaired B-type Natriuretic Peptide Effets on Neutrophil Burst in Heart Failure Patients

Doan T.M. Ngo - American Heart Association (AHA) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Nesiritide

Filters

387 Abstracts